Please Scroll Down to See Forums Below 
DJLegacy2k1
New member
Natural stuff should be fine if you stayed at 50mg ed, HCGenerate+UNLEASHED should workout or add in Sustain Alpha and see how you do.
-Legacy
SARMS-s4 Study
- Thread starter DJLegacy2k1
- Start date
Natural stuff should be fine if you stayed at 50mg ed, HCGenerate+UNLEASHED should workout or add in Sustain Alpha and see how you do.
-Legacy
truckdaddy
Banned
Sarms has NEVER shut me down and I would not listen to anything that ross has to say.
DJLegacy2k1
New member
Understandable, but this clinical trial and I know I have 1 or 2 more somewhere that all stated that Shutdown was present, to what degree Im sure varies and is dose dependent, but they all showed shutdown to some degree after a certain dose and time frame. Im still looking to find where I saved the others.
-Legacy
DJLegacy2k1
New member
SARMS-s4 Study #2:
Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit - Journal of Medicinal Chemistry (ACS Publications)
3602 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 12 Award Address
Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit - Journal of Medicinal Chemistry (ACS Publications)
Section 1.5.2. Nonsteroidal AR Agonists. The Propionamides.
..the resulting compound known
in the literature as S-4 and in press releases as andarine (S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
trifluoromethylphenyl)propionamide) was
shown to possess SARM activity and allowed the pharmacodynamic exploration of this novel class of drugs.
Section 2.1.7. Andarine, the Prototypical Full Efficacy SARM.
Andarine was a SARM that served as the predominant model compound early in the development of the SARM field. Many of the landmark studies with andarine served as proofs-of-concept in the SARM field (e.g., concomitant myo- and osteoanabolism in the absence of VP proliferation, musculoskeletal performance enhancement, etc.). Preclinical characterization of andarine demonstrated high binding affinity for AR (Ki ) 4 nM) and ideal pharmacokinetics (complete oral bioavailability, plasma half-life consistent with daily oral dosing in rats and dogs) with no cross-reactivity with the other nuclear receptors. Myoanabolism was demonstrated in terms of maintenance and restoration of LA weight and restoration of soleus muscle strength in castrated rats. Likewise, osteoanabolism was observed in maintenance and restorative modes in male and female rats with improvements in biomechanical strength, cumulatively demonstrating musculoskeletal performance enhancement. The anabolic effects were also observed at the level of the entire organism as revealed by favorable body composition changes. Importantly, these anabolic effects were tissue-selective when compared to androgenic tissue and HPG axis effects, establishing andarine as a prototypical preclinical SARM. The peripheral and selective anabolic preclinical pharmacodynamic profile of andarine seemed highly promising and stimulated us to pursue landmark clinical trials of the SARMs, andarine and Ostarine. Although phase I studies with andarine were successful with no deficiencies noted , Ostarine was selected for advanced clinical development based on corporate strategy. Readers are cautioned to note that the name Ostarine is often mistakenly linked to the chemical structure of andarine. The chemical structure of Ostarine has not been publicly disclosed. The authors are unable to provide additional information. Collectively, these preclinical and clinical studies have provided the foundation for the massive body of SARM characterizations that are now published and patented (discussed below). Importantly, many of these pharmacodynamic observations have proven to be typical of subsequently published chemodiverse SARMs, as discussed in section 3.
-Legacy
Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit - Journal of Medicinal Chemistry (ACS Publications)
3602 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 12 Award Address
Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit - Journal of Medicinal Chemistry (ACS Publications)
Section 1.5.2. Nonsteroidal AR Agonists. The Propionamides.
..the resulting compound known
in the literature as S-4 and in press releases as andarine (S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
trifluoromethylphenyl)propionamide) was
shown to possess SARM activity and allowed the pharmacodynamic exploration of this novel class of drugs.
Section 2.1.7. Andarine, the Prototypical Full Efficacy SARM.
Andarine was a SARM that served as the predominant model compound early in the development of the SARM field. Many of the landmark studies with andarine served as proofs-of-concept in the SARM field (e.g., concomitant myo- and osteoanabolism in the absence of VP proliferation, musculoskeletal performance enhancement, etc.). Preclinical characterization of andarine demonstrated high binding affinity for AR (Ki ) 4 nM) and ideal pharmacokinetics (complete oral bioavailability, plasma half-life consistent with daily oral dosing in rats and dogs) with no cross-reactivity with the other nuclear receptors. Myoanabolism was demonstrated in terms of maintenance and restoration of LA weight and restoration of soleus muscle strength in castrated rats. Likewise, osteoanabolism was observed in maintenance and restorative modes in male and female rats with improvements in biomechanical strength, cumulatively demonstrating musculoskeletal performance enhancement. The anabolic effects were also observed at the level of the entire organism as revealed by favorable body composition changes. Importantly, these anabolic effects were tissue-selective when compared to androgenic tissue and HPG axis effects, establishing andarine as a prototypical preclinical SARM. The peripheral and selective anabolic preclinical pharmacodynamic profile of andarine seemed highly promising and stimulated us to pursue landmark clinical trials of the SARMs, andarine and Ostarine. Although phase I studies with andarine were successful with no deficiencies noted , Ostarine was selected for advanced clinical development based on corporate strategy. Readers are cautioned to note that the name Ostarine is often mistakenly linked to the chemical structure of andarine. The chemical structure of Ostarine has not been publicly disclosed. The authors are unable to provide additional information. Collectively, these preclinical and clinical studies have provided the foundation for the massive body of SARM characterizations that are now published and patented (discussed below). Importantly, many of these pharmacodynamic observations have proven to be typical of subsequently published chemodiverse SARMs, as discussed in section 3.
-Legacy
There are almost a dozen different anabolic steroids that you could use for specific recomposition goals, with minimal sides and no need for a "hardcore PCT"; Methenolone, Boldenone, Drostanolone, Oxandrolone, fluoxymesterone, Turinabol, Stanozolol, Testosterone undecanoate...
You should also know, there are many different SARMS. None of the SARMs yet developed are truly selective for anabolic effects in muscle or bone tissues without producing any androgenic effects in tissues such as the prostate gland, however several non-steroidal androgens show a ratio of anabolic to androgenic effects of greater than 3:1 and up to as much as 10:1, compared to testosertone which has a ratio of 1:1.
These are the SARMS currently available:
AC-262,356[10]
Andarine ("S-4") - partial agonist, intended mainly for treatment of benign prostatic hypertrophy
BMS-564,929 - mainly affects muscle growth, intended as general treatment for symptoms of andropause
JNJ-28330835.[11][12]
LGD-2226 - affects both muscle and bone
LGD-3303[13]
Ostarine [14] - affects both muscle and bone, intended mainly for osteoporosis but also general treatment for andropause
S-23 - under development as a male hormonal contraceptive[15]
S-40503 - selective for bone tissue, particularly low virilization, intended for osteoporosis and may be suitable for use in women
^ Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, Vanover KE, Davis RE, Olsson R, Bradley SR (March 2008). "Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator". J. Steroid Biochem. Mol. Biol. 109 (1-2): 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613.
^ Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z (January 2007). "Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators". Bioorganic & Medicinal Chemistry Letters 17 (2): 439–43. doi:10.1016/j.bmcl.2006.10.035. PMID 17079140.
^ Allan GF, Tannenbaum P, Sbriscia T, et al. (2007). "A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats". Endocrine 32 (1): 41–51. doi:10.1007/s12020-007-9005-2. PMID 17992601.
^ Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH (February 2009). "Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator". J. Pharmacol. Exp. Ther. 328 (2): 663–70. doi:10.1124/jpet.108.146811. PMID 19017848.
^ Kearbey JD, Gao W, Narayanan R, et al. (2007). "Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats". Pharm. Res. 24 (2): 328–35. doi:10.1007/s11095-006-9152-9. PMID 17063395.
^ Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT (January 2009). "Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception". Endocrinology 150 (1): 385–95. doi:10.1210/en.2008-0674. PMID 18772237.
DJLegacy2k1
New member
I know all about the different SARMS but some downfalls to the other said compounds some include: Cost, effectiveness, joint pains, methylated, liver/kidney issues, injections (for some an issue). I mean EVERYTHING has its downside, I for one ran Var for 6 weeks and didnt think the results were worth the cost for example. There are logs on numerous boards of people having good recomp results and all SARMS studies so far make some mentions of Body Comp shifts to the positive.
I do agree that their are MANY compounds that do good work but ALL have downfalls, if there was 1 or 2 compounds that worked perfectly with no downside there wouldnt be the need for 50 different options, they all have their place. People with higher levels of fat need to be careful with many of the compounds and monitor the release of estrogen into their bodies and aromatization so that they dont do more harm than good. Obviously they can counter this with other medical compounds but again we are talking about their ability to run these compounds successfully to get the desired results. SARMS seem to be much milder, slow, steady, consistent, for most people.
Just stating that I think SARMS does have a place for SOME people for recomp projects along with things like the LIPOSHRED stack from OMEGA, if they want to avoid some of the other "issues" with other compounds.
Just friendly discussion
-Legacy
I do agree that their are MANY compounds that do good work but ALL have downfalls, if there was 1 or 2 compounds that worked perfectly with no downside there wouldnt be the need for 50 different options, they all have their place. People with higher levels of fat need to be careful with many of the compounds and monitor the release of estrogen into their bodies and aromatization so that they dont do more harm than good. Obviously they can counter this with other medical compounds but again we are talking about their ability to run these compounds successfully to get the desired results. SARMS seem to be much milder, slow, steady, consistent, for most people.
Just stating that I think SARMS does have a place for SOME people for recomp projects along with things like the LIPOSHRED stack from OMEGA, if they want to avoid some of the other "issues" with other compounds.
Just friendly discussion
-Legacy
DJLegacy2k1
New member
lol, I do what I can
-Legacy
-Legacy
S4 isn't for muscle growth.
DJLegacy2k1
New member
I think most people are using it for this quote Ross: "The anabolic effects were also observed at the level of the entire organism as revealed by favorable body composition changes."
-Legacy
